Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1839]

Combination of capecitabine and bevacizumab improves progression-free survival...

Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France

Combination of capecitabine and bevacizumab improves progression-free survival in metastatic breast cancer ( Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

The evolving treatment landscape for HER2-positive metastatic breast cancer

Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium

The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )

Navigating current treatment options for HER2-positive MBC: Patient journey 1

Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria

Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )

ecancermedicalscience editor's choice for September 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for September 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

ecancermedicalscience editor's choice for July and August 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for July and August 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Metronomics and low/middle income countries, especially in breast cancer

Dr Alexandru Eniu - Cancer Institute Ion Chiricuta Cluj-Napoca, Cluj-Napoca...

Metronomics and low/middle income countries, especially in breast cancer ( Dr Alexandru Eniu - Cancer Institute Ion Chiricuta Cluj-Napoca, Cluj-Napoca, Romania )

Drug repurposing as an alternative to costly drugs such as herceptin in breast...

Dr Shripad Banavali - Tata Memorial Hospital, Mumbai, India

Drug repurposing as an alternative to costly drugs such as herceptin in breast cancer ( Dr Shripad Banavali - Tata Memorial Hospital, Mumbai, India )

Diabetes drug, metformin, repurposed for use against several cancers including...

Dr Francesco Bertolini - European Institute of Oncology, Milan, Italy

Diabetes drug, metformin, repurposed for use against several cancers including breast ( Dr Francesco Bertolini - European Institute of Oncology, Milan, Italy )

Networking and collaborating across borders in sub-Saharan Africa

Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer...

Networking and collaborating across borders in sub-Saharan Africa ( Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer Centre, Houston, USA )

Work of the WIN consortium and challenges of personalised cancer therapy

Prof John Mendelsohn - University of Texas MD Anderson Cancer Center, Houston...

Work of the WIN consortium and challenges of personalised cancer therapy ( Prof John Mendelsohn - University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer